WuXi AppTec · 603259.SH · CNY
Strong weekly trend, uncertain daily entry
WuXi AppTec (药明康德, 603259.SH) stock analysis with real CNY quotes and daily/weekly K-lines. Compare a strong weekly trend with daily selling pressure, pullback confirmation, support and resistance, CRDMO and TIDES demand, and dated 1260H policy and litigation evidence.
The recorded quote and analysis refer to their labeled snapshot dates. A newer public quote may load separately; the analysis is not recalculated.
Research view captured
The recorded close is CN¥157.80, with a session move of -2.59%, seven-session return -5.99%, and 7.83% drawdown from the last 30 sessions’ high. Daily volume expanded to 1.77× its prior 20-session average. Daily RSI 48.8 is near neutral, the MACD histogram is negative (-0.6524), and price is below EMA20 CN¥160.34 but above EMA50 CN¥151.80. Weekly RSI 66.4 and an upward weekly SuperTrend support the larger trend. My view is mixed: a potentially tradable pullback inside a strong weekly structure, with unconfirmed daily timing and material headline risk.
I would first watch whether the CN¥153.26–151.62 area and daily EMA50 CN¥151.80 remain defended. A completed daily EMA20 CN¥160.34 reclaim, then a close above the October 9 high CN¥162.50 and a held retest, would improve the rebound case toward CN¥166.15 and CN¥171.20. Losing the recent CN¥149.70 low would weaken the pullback thesis; weekly EMA20 near CN¥140.77 is a broader reference, not a guaranteed exit or a near-term floor.
Recorded conversation · no orders sent
October 9, 2026 · completed cash-stock session
WuXi AppTec opened at CN¥162, traded between CN¥151.62 and CN¥162.50, and closed at CN¥157.80, with a session move of -2.59%. It recovered part of the intraday loss, yet did not reclaim the prior CN¥162 close. About 60,449,700 shares and CNY 9.417 billion traded. Higher participation can include distribution as well as demand; the daily bar cannot identify who bought.
RSI 48.8 is not an oversold signal. The negative MACD histogram -0.6524 indicates fading daily momentum even though the MACD line remains above zero. Volume 1.77× and a close below EMA20 CN¥160.34 require more confirmation than simply pointing to the weekly uptrend.
Weekly RSI is 66.4; price is above weekly EMA20 CN¥140.77 and EMA50 CN¥117.95, with positive MACD momentum and upward SuperTrend. That supports the larger structure, not an immediate buy at every price. The latest week has only October 8–9 after the holiday, so its 0.40× ordinary-week volume cannot be read as a like-for-like weakness signal.
EMA20
CN¥160.34
EMA50
CN¥151.80
EMA200
CN¥120.97
RSI(14)
48.83
MACD(12,26,9)
2.6129
MACD histogram
-0.6524
Bollinger(20,2)
CN¥149.35 – CN¥170.00
ATR(14)
CN¥6.61
VWAP · displayed calculation history
CN¥73.85
K / D / J
43.2 / 53.7 / 22.1
SuperTrend(10,3)
Up
Volume / previous 20 bars
1.77×
Last completed candle: · 1000 bars used for indicators
Recorded cash-stock data · example conversation. CNY prices; share volume; forward-adjusted (qfq) history. The quote and chart timestamps refer to different observations.
The observed CN¥153.26 pivot, daily EMA50 CN¥151.80, and October 9 low CN¥151.62 form nearby reference points. Watch whether a later retest stops making lower lows and actually regains strength. I would not infer that the intraday recovery guarantees support or that every dip toward this area should be bought.
First reclaim daily EMA20 CN¥160.34; then close above CN¥162.50 and defend a later retest. The CN¥166.15 historical swing high and CN¥171.20 recent high are subsequent checkpoints. A brief intraday crossing or a news-driven gap without a held retest is weaker evidence.
Losing CN¥151.62, then sustaining a break below CN¥149.70, would challenge the current pullback structure. Weekly EMA20 CN¥140.77 is farther away and should not quietly replace a nearer invalidation plan. A headline gap can move through reference levels before an executable exit is available.
Recorded cash-stock data · example conversation. CNY prices; share volume; forward-adjusted (qfq) history. The quote and chart timestamps refer to different observations.
Illustration, not an order: 100 shares bought at CN¥157.80 and later sold at CN¥149.70 lose CN¥810 before fees. A move to CN¥162.50 adds CN¥470—about 0.58× that reference risk. Daily ATR CN¥6.61 is a volatility estimate, not a maximum possible loss. Gaps, liquidity and T+1 can make the actual result worse than a planned chart exit.
The August 7, 2026 court opinion granted preliminary relief concerning the Section 1260H designation; the company added an update to its June 12 statement. That is not a final merits judgment or a guarantee of customer orders. Read the court document separately from the company’s position, and check later docket and policy developments. This page does not determine the current scope of U.S. restrictions or prove that policy risk has disappeared.
Court opinion · August 7, 2026 (Justia mirror)The 2026 half-year report records revenue growth of 38.93%, attributable net-profit growth of 29.43%, and operating cash-flow growth of 30.52%. The September 22 capacity article discusses CRDMO, peptide, and oligonucleotide demand. These are different business signals from a daily entry trigger; verify project conversion, utilization, cash collection, and expectations before treating a theme as realized future revenue.
603259.SH is the Shanghai main-board cash stock in CNY, distinct from its Hong Kong listing and from WuXi Biologics. Ordinary opening buys use 100-share multiples: 100 shares at CN¥157.80 cost about CN¥15,780 before fees. The usual daily price band is 10%, with exceptions; newly bought shares generally cannot be sold that day under T+1. Confirm broker permissions and current rules. Coinseer does not execute China stock orders.
Evidence from the recorded analysis below.
Defending CN¥153.26–151.62, then reclaiming EMA20 CN¥160.34 and holding a completed close above CN¥162.50, would improve the rebound scenario. Watch CN¥166.15 and CN¥171.20 as conditional checkpoints, not promised targets.
Failure below CN¥151.62 followed by a sustained loss of CN¥149.70 would weaken the pullback thesis. Weekly EMA20 near CN¥140.77 is a wider structural reference, not a substitute exit plan. A policy-related gap can bypass support.
Conditional reference scenarios at the recorded research time.
Recent themes worth checking. These sources provide context, not proof of the cause of today’s move. Verify price, volume, and timing together.
Sources reviewed ·
The half-year report records revenue growth of 38.93%, attributable net-profit growth of 29.43%, and operating cash-flow growth of 30.52%. Those figures provide operating context; they do not by themselves explain the October 9 price decline or guarantee new orders.
WuXi AppTec · 2026 half-year reportPublished ·
The September 22 issuer article discusses global capacity and demand for specialized drug manufacturing. Treat expansion and management expectations separately from realized utilization, customer project conversion, and cash returns.
WuXi AppTec · Global manufacturing capacityPublished ·
The company’s June 12 statement includes an August 7 preliminary-injunction update. It is an issuer statement; read the court opinion and subsequent developments separately. Preliminary relief does not establish that every policy or customer risk has disappeared.
WuXi AppTec · 1260H legal-action statement (August 7 update)Published ·
Your question is editable; nothing is sent automatically.
Your research partner
Understand the A-share evidence, test conflicting signals, and learn the indicators with cash-stock data. Stock trading decisions remain with you and your broker.
Read cash-stock quotes and historical charts in one conversation. Follow the data timestamp and use your broker to verify executable prices.
Assess daily and weekly trend, momentum, volatility, and volume together rather than treating one indicator as a buy signal.
Build on the evidence already discussed and ask targeted follow-ups, reducing repetitive explanations. Credit use still depends on the model and request.
Ask what RSI, moving averages, MACD, or a lower wick means on real stock charts, including when signals disagree.
Explore a reclaim, a failed retest, and downside invalidation separately. Include the T+1 constraint before considering a cash-stock entry.
Coinseer provides A-share research, not stock order execution. Review access, position size, fees, and overnight liquidity with your broker.
Name the asset, timeframe, or concern. A clear question is enough to begin.
Look at the charts and compare the signals the agent brings into the conversation.
Ask what would change the view, then choose your next step with the risks visible.
A weekly uptrend and a daily entry are separate decisions. Look for a defended reference area and completed daily repair, then compare the available upside with invalidation distance, fees, and overnight risk. Do not stretch a short-term trade into a longer hold just because a lower weekly average exists.
Capacity expansion, customer projects, revenue recognition, and cash collection are distinct stages. Legal relief, management statements, and commercial orders are also different kinds of evidence. Review source dates and current documents before turning a popular pharmaceutical theme or headline into a trading conclusion.
The chart uses 1,000 completed daily sessions and 211 completed weekly candles, with qfq-adjusted CNY history and share volume. The latest unadjusted quote reconciles to the captured close. Corporate actions may change historical levels. Returns and drawdowns count trading sessions; no hourly price target is invented from daily bars. Refreshed quotes do not revise the recorded analysis.
WuXi AppTec Co., Ltd., Shanghai main-board cash stock 603259.SH in CNY. It does not substitute Hong Kong prices and is not WuXi Biologics or a stock perpetual.
At the October 9, 2026 close of CNY 157.80, the session fell 2.59% on about 1.77× recent average volume. Weekly RSI was strong at 66.4, but the close was below daily EMA20 and daily momentum was fading. A defended retest and completed daily repair would improve the case; the weekly chart alone is insufficient.
Recorded references include CNY 153.26, daily EMA50 near CNY 151.80, and the session low CNY 151.62; CNY 149.70 is a recent failure reference. Above: daily EMA20 around CNY 160.34, the CNY 162.50 session high, then CNY 166.15 and 171.20. Recalculate with fresh data; no exit is guaranteed.
No. The August 7, 2026 document concerns preliminary relief, not a final merits judgment or customer order guarantee. Read the court opinion, issuer disclosures, and later developments separately. This research page does not determine the current legal scope of U.S. restrictions.
Coinseer provides China stock research and charts, not stock order execution. Newly purchased shares generally cannot be sold the same day. Gaps, price limits and liquidity can prevent a planned exit. Verify executable prices, access, and current rules with your broker.
Ask your own WuXi AppTec question about pullback timing, daily-versus-weekly signals, CRDMO demand, or headline risk. Start with the evidence and your trading horizon.
Ask coinseerWuXi AppTec · 603259.SH · CNY
Strong weekly trend, uncertain daily entry
WuXi AppTec (药明康德, 603259.SH) stock analysis with real CNY quotes and daily/weekly K-lines. Compare a strong weekly trend with daily selling pressure, pullback confirmation, support and resistance, CRDMO and TIDES demand, and dated 1260H policy and litigation evidence.
The recorded quote and analysis refer to their labeled snapshot dates. A newer public quote may load separately; the analysis is not recalculated.
Research view captured
The recorded close is CN¥157.80, with a session move of -2.59%, seven-session return -5.99%, and 7.83% drawdown from the last 30 sessions’ high. Daily volume expanded to 1.77× its prior 20-session average. Daily RSI 48.8 is near neutral, the MACD histogram is negative (-0.6524), and price is below EMA20 CN¥160.34 but above EMA50 CN¥151.80. Weekly RSI 66.4 and an upward weekly SuperTrend support the larger trend. My view is mixed: a potentially tradable pullback inside a strong weekly structure, with unconfirmed daily timing and material headline risk.
I would first watch whether the CN¥153.26–151.62 area and daily EMA50 CN¥151.80 remain defended. A completed daily EMA20 CN¥160.34 reclaim, then a close above the October 9 high CN¥162.50 and a held retest, would improve the rebound case toward CN¥166.15 and CN¥171.20. Losing the recent CN¥149.70 low would weaken the pullback thesis; weekly EMA20 near CN¥140.77 is a broader reference, not a guaranteed exit or a near-term floor.
Recorded conversation · no orders sent
October 9, 2026 · completed cash-stock session
WuXi AppTec opened at CN¥162, traded between CN¥151.62 and CN¥162.50, and closed at CN¥157.80, with a session move of -2.59%. It recovered part of the intraday loss, yet did not reclaim the prior CN¥162 close. About 60,449,700 shares and CNY 9.417 billion traded. Higher participation can include distribution as well as demand; the daily bar cannot identify who bought.
RSI 48.8 is not an oversold signal. The negative MACD histogram -0.6524 indicates fading daily momentum even though the MACD line remains above zero. Volume 1.77× and a close below EMA20 CN¥160.34 require more confirmation than simply pointing to the weekly uptrend.
Weekly RSI is 66.4; price is above weekly EMA20 CN¥140.77 and EMA50 CN¥117.95, with positive MACD momentum and upward SuperTrend. That supports the larger structure, not an immediate buy at every price. The latest week has only October 8–9 after the holiday, so its 0.40× ordinary-week volume cannot be read as a like-for-like weakness signal.
EMA20
CN¥160.34
EMA50
CN¥151.80
EMA200
CN¥120.97
RSI(14)
48.83
MACD(12,26,9)
2.6129
MACD histogram
-0.6524
Bollinger(20,2)
CN¥149.35 – CN¥170.00
ATR(14)
CN¥6.61
VWAP · displayed calculation history
CN¥73.85
K / D / J
43.2 / 53.7 / 22.1
SuperTrend(10,3)
Up
Volume / previous 20 bars
1.77×
Last completed candle: · 1000 bars used for indicators
Recorded cash-stock data · example conversation. CNY prices; share volume; forward-adjusted (qfq) history. The quote and chart timestamps refer to different observations.
The observed CN¥153.26 pivot, daily EMA50 CN¥151.80, and October 9 low CN¥151.62 form nearby reference points. Watch whether a later retest stops making lower lows and actually regains strength. I would not infer that the intraday recovery guarantees support or that every dip toward this area should be bought.
First reclaim daily EMA20 CN¥160.34; then close above CN¥162.50 and defend a later retest. The CN¥166.15 historical swing high and CN¥171.20 recent high are subsequent checkpoints. A brief intraday crossing or a news-driven gap without a held retest is weaker evidence.
Losing CN¥151.62, then sustaining a break below CN¥149.70, would challenge the current pullback structure. Weekly EMA20 CN¥140.77 is farther away and should not quietly replace a nearer invalidation plan. A headline gap can move through reference levels before an executable exit is available.
Recorded cash-stock data · example conversation. CNY prices; share volume; forward-adjusted (qfq) history. The quote and chart timestamps refer to different observations.
Illustration, not an order: 100 shares bought at CN¥157.80 and later sold at CN¥149.70 lose CN¥810 before fees. A move to CN¥162.50 adds CN¥470—about 0.58× that reference risk. Daily ATR CN¥6.61 is a volatility estimate, not a maximum possible loss. Gaps, liquidity and T+1 can make the actual result worse than a planned chart exit.
The August 7, 2026 court opinion granted preliminary relief concerning the Section 1260H designation; the company added an update to its June 12 statement. That is not a final merits judgment or a guarantee of customer orders. Read the court document separately from the company’s position, and check later docket and policy developments. This page does not determine the current scope of U.S. restrictions or prove that policy risk has disappeared.
Court opinion · August 7, 2026 (Justia mirror)The 2026 half-year report records revenue growth of 38.93%, attributable net-profit growth of 29.43%, and operating cash-flow growth of 30.52%. The September 22 capacity article discusses CRDMO, peptide, and oligonucleotide demand. These are different business signals from a daily entry trigger; verify project conversion, utilization, cash collection, and expectations before treating a theme as realized future revenue.
603259.SH is the Shanghai main-board cash stock in CNY, distinct from its Hong Kong listing and from WuXi Biologics. Ordinary opening buys use 100-share multiples: 100 shares at CN¥157.80 cost about CN¥15,780 before fees. The usual daily price band is 10%, with exceptions; newly bought shares generally cannot be sold that day under T+1. Confirm broker permissions and current rules. Coinseer does not execute China stock orders.
Evidence from the recorded analysis below.
Defending CN¥153.26–151.62, then reclaiming EMA20 CN¥160.34 and holding a completed close above CN¥162.50, would improve the rebound scenario. Watch CN¥166.15 and CN¥171.20 as conditional checkpoints, not promised targets.
Failure below CN¥151.62 followed by a sustained loss of CN¥149.70 would weaken the pullback thesis. Weekly EMA20 near CN¥140.77 is a wider structural reference, not a substitute exit plan. A policy-related gap can bypass support.
Conditional reference scenarios at the recorded research time.
Recent themes worth checking. These sources provide context, not proof of the cause of today’s move. Verify price, volume, and timing together.
Sources reviewed ·
The half-year report records revenue growth of 38.93%, attributable net-profit growth of 29.43%, and operating cash-flow growth of 30.52%. Those figures provide operating context; they do not by themselves explain the October 9 price decline or guarantee new orders.
WuXi AppTec · 2026 half-year reportPublished ·
The September 22 issuer article discusses global capacity and demand for specialized drug manufacturing. Treat expansion and management expectations separately from realized utilization, customer project conversion, and cash returns.
WuXi AppTec · Global manufacturing capacityPublished ·
The company’s June 12 statement includes an August 7 preliminary-injunction update. It is an issuer statement; read the court opinion and subsequent developments separately. Preliminary relief does not establish that every policy or customer risk has disappeared.
WuXi AppTec · 1260H legal-action statement (August 7 update)Published ·
Your question is editable; nothing is sent automatically.
Your research partner
Understand the A-share evidence, test conflicting signals, and learn the indicators with cash-stock data. Stock trading decisions remain with you and your broker.
Read cash-stock quotes and historical charts in one conversation. Follow the data timestamp and use your broker to verify executable prices.
Assess daily and weekly trend, momentum, volatility, and volume together rather than treating one indicator as a buy signal.
Build on the evidence already discussed and ask targeted follow-ups, reducing repetitive explanations. Credit use still depends on the model and request.
Ask what RSI, moving averages, MACD, or a lower wick means on real stock charts, including when signals disagree.
Explore a reclaim, a failed retest, and downside invalidation separately. Include the T+1 constraint before considering a cash-stock entry.
Coinseer provides A-share research, not stock order execution. Review access, position size, fees, and overnight liquidity with your broker.
Name the asset, timeframe, or concern. A clear question is enough to begin.
Look at the charts and compare the signals the agent brings into the conversation.
Ask what would change the view, then choose your next step with the risks visible.
A weekly uptrend and a daily entry are separate decisions. Look for a defended reference area and completed daily repair, then compare the available upside with invalidation distance, fees, and overnight risk. Do not stretch a short-term trade into a longer hold just because a lower weekly average exists.
Capacity expansion, customer projects, revenue recognition, and cash collection are distinct stages. Legal relief, management statements, and commercial orders are also different kinds of evidence. Review source dates and current documents before turning a popular pharmaceutical theme or headline into a trading conclusion.
The chart uses 1,000 completed daily sessions and 211 completed weekly candles, with qfq-adjusted CNY history and share volume. The latest unadjusted quote reconciles to the captured close. Corporate actions may change historical levels. Returns and drawdowns count trading sessions; no hourly price target is invented from daily bars. Refreshed quotes do not revise the recorded analysis.
WuXi AppTec Co., Ltd., Shanghai main-board cash stock 603259.SH in CNY. It does not substitute Hong Kong prices and is not WuXi Biologics or a stock perpetual.
At the October 9, 2026 close of CNY 157.80, the session fell 2.59% on about 1.77× recent average volume. Weekly RSI was strong at 66.4, but the close was below daily EMA20 and daily momentum was fading. A defended retest and completed daily repair would improve the case; the weekly chart alone is insufficient.
Recorded references include CNY 153.26, daily EMA50 near CNY 151.80, and the session low CNY 151.62; CNY 149.70 is a recent failure reference. Above: daily EMA20 around CNY 160.34, the CNY 162.50 session high, then CNY 166.15 and 171.20. Recalculate with fresh data; no exit is guaranteed.
No. The August 7, 2026 document concerns preliminary relief, not a final merits judgment or customer order guarantee. Read the court opinion, issuer disclosures, and later developments separately. This research page does not determine the current legal scope of U.S. restrictions.
Coinseer provides China stock research and charts, not stock order execution. Newly purchased shares generally cannot be sold the same day. Gaps, price limits and liquidity can prevent a planned exit. Verify executable prices, access, and current rules with your broker.
Ask your own WuXi AppTec question about pullback timing, daily-versus-weekly signals, CRDMO demand, or headline risk. Start with the evidence and your trading horizon.
Ask coinseer